Global Neoantigen Cancer Vaccine Market is expected to grow at a 20.0% CAGR during the forecast period for 2025-2034.
Neoantigen Cancer Vaccines are vaccines that assist in boosting the immune system by using a single or several antigens. The antigens generally consist of several peptides or proteins. Neoantigens are a mutated or a new type of antigen present only in cancer cells and not in rest normal cells. Neoantigen Cancer Vaccines stimulate the new T-cell response against the mutated antigens present in the cancer cells.
Neoantigen Cancer Vaccine has recorded with proven effectiveness and satisfactory results in clinical trials test of cancer treatment. Increasing cases for cancer patients across the globe and rising focus on specific & effective cancer management treatments are propelling the demand for oncology drugs and apparently boosting the market for global Neoantigen Cancer Vaccine market. Increasing emphasis on personalized cancer treatment and rising economic burden due to cancer treatment procedures has led the pharmaceutical manufacturers to invest significantly in research and development activities in order to fulfil the existing as well as latent demand for Neoantigen Cancer Vaccine.
The neoantigen cancer vaccines market is segmented on the basis of product, neovaccine type, therapy type, and region. Based on the products, the market is divided into Personalized neoantigens vaccines and Off-the-shelf Neoantigen vaccines. On the basis of neovaccine type, the market is segmented into Nucleic acid/DNA/mRNA Vaccine, Peptide Vaccines, and Dendritic Cell-based Vaccines. Based on region, the market is studied across North America, Asia-Pacific, Europe, and the Rest of World. North America is expected to dominate the market during the analysis of the forecast period.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 20.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Neovaccine Type, By Therapeutic Area By Therapy Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Moderna Therapeutics/Merck, Advaxis, Agenus, Genocea Biosciences Inc, Gritstone Oncology, Neon Therapeutics, Nouscom, OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, Vaccibody, Brightpath Biotherapeutics, Geneos Therapeutics, Frame Therapeutics, Immunetune, NeoPhore, and CureVac AG., and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neoantigen Cancer Vaccine Market Snapshot
Chapter 4. Global Neoantigen Cancer Vaccine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Neoantigen Cancer Vaccine Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Neoantigen Cancer Vaccine Market Industry Trends
Chapter 5. Neoantigen Cancer Vaccine Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Personalized Neoantigens vaccines
5.2.2. Off-the-shelf Neoantigen vaccines
Chapter 6. Neoantigen Cancer Vaccine Market Segmentation 2: By Neovaccine Type, Estimates & Trend Analysis
6.1. Market Share by Neovaccine Type, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Neovaccine Type:
6.2.1. Nucleic acid/DNA/mRNA Vaccine
6.2.2. Peptide Vaccines
6.2.3. Dendritic Cell–based Vaccines
Chapter 7. Neoantigen Cancer Vaccine Market Segmentation 3: By Therapy Type, Estimates & Trend Analysis
7.1. Market Share by Therapy Type, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type:
7.2.1. Mono Therapeutic Regimens
7.2.2. Combinatorial Regimens
Chapter 8. Neoantigen Cancer Vaccine Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Neoantigen Cancer Vaccine Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.2.3. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.2.4. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
8.3. Europe
8.3.1. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.3.3. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.3.4. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.4.3. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.4.4. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts By Therapy Type, 2021-2034
8.5. Latin America
8.5.1. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.5.3. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.5.4. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.6.3. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.6.4. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Roche
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Medimmune
9.2.3. Moderna Therapeutics/Merck
9.2.4. Advaxis
9.2.5. Agenus
9.2.6. Genocea Biosciences Inc
9.2.7. Gritstone Oncology
9.2.8. Neon Therapeutics
9.2.9. Nouscom
9.2.10. OSE Immunotherapeutics
9.2.11. Immunovative Therapeutics
9.2.12. Medigene
9.2.13. Vaccibody
9.2.14. Brightpath Biotherapeutics
9.2.15. Geneos Therapeutics
9.2.16. Frame Therapeutics
9.2.17. Immunetune
9.2.18. NeoPhore
9.2.19. CureVac AG
9.2.20. Other Prominent Players
Global Neoantigen Cancer Vaccine Market by Product
Global Neoantigen Cancer Vaccine Market Based on Neovaccine Type
Global Neoantigen Cancer Vaccine Market Based on Therapy Type
Global Neoantigen Cancer Vaccine Market Based on Region
Europe Neoantigen Cancer Vaccine Market Outlook,
North America Neoantigen Cancer Vaccine Market Outlook,
Asia Pacific Neoantigen Cancer Vaccine Market Outlook,